ConductScience.org, home

Paper41358882

8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.

American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care, 2026. Cited by 55 papers, by iCite.

Cite this record

ConductScience Library. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026. Papers, record 41358882. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41358882

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.
PubMed
Journal
Diabetes Care
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
55
iCite
Relative citation ratio, by iCite
34.43, provisional
iCite
Revised in PubMed
2026-06-25
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1American Diabetes Association Professional Practice Committee for Diabetes*Group

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ObesityMajor topic
Diabetes MellitusMajor topic
Standard of CareMajor topic
Humans

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07835360Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 DiabetesBackground

Source ClinicalTrials.gov

Download CSV of trials

References178

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135533384Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds.Ann Intern Med2022https://conductscience.org/library/papers/35533384PubMed
228388637Unintentional weight loss: Clinical characteristics and outcomes in a prospective cohort of 2677 patients.PLoS One2017https://conductscience.org/library/papers/28388637PubMed
314726171Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.Lancet2004https://conductscience.org/library/papers/14726171PubMed
437385275Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2023https://conductscience.org/library/papers/37385275PubMed
524915261Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.JAMA2014https://conductscience.org/library/papers/24915261PubMed
634170647Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med2021https://conductscience.org/library/papers/34170647PubMed
726201412Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York.Surg Endosc2016https://conductscience.org/library/papers/26201412PubMed
823560285Substance use following bariatric weight loss surgery.JAMA Surg2013https://conductscience.org/library/papers/23560285PubMed
99702435Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.Diabetes Care1998https://conductscience.org/library/papers/9702435PubMed
1036280539
2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery.
Surg Obes Relat Dis2022https://conductscience.org/library/papers/36280539PubMed
1135196654Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement.Obes Facts2022https://conductscience.org/library/papers/35196654PubMed
1225547054Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2.Surg Obes Relat Dis2015https://conductscience.org/library/papers/25547054PubMed
1321481449
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Lancet2011https://conductscience.org/library/papers/21481449PubMed
1432896055What exercise prescription is optimal to improve body composition and cardiorespiratory fitness in adults living with obesity? A network meta-analysis.Obes Rev2021https://conductscience.org/library/papers/32896055PubMed
1527328752The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.Int J Obes (Lond)2016https://conductscience.org/library/papers/27328752PubMed
1637700013Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study.Surg Endosc2023https://conductscience.org/library/papers/37700013PubMed
1727222552Bariatric Surgery in Obese Patients With Type 1 Diabetes.Diabetes Care2016https://conductscience.org/library/papers/27222552PubMed
18384230265-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study.Lancet Diabetes Endocrinol2024https://conductscience.org/library/papers/38423026PubMed
1934435943Culturally tailored lifestyle interventions for the prevention and management of type 2 diabetes in adults of Black African ancestry: a systematic review of tailoring methods and their effectiveness.Public Health Nutr2022https://conductscience.org/library/papers/34435943PubMed
2038887616
Effects of combined aerobic and resistance training on glycemic control, blood pressure, inflammation, cardiorespiratory fitness and quality of life in patients with type 2 diabetes and overweight/obesity: a systematic review and meta-analysis.
PeerJ2024https://conductscience.org/library/papers/38887616PubMed

See all 178 referencesDownload CSV of references

Cited by50

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.

PMIDTitleJournalYearIn PapersSource
42985198Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42985198PubMed
42979537Balancing clinical benefits and behavioral risks of obesity-focused management in youth-onset type 2 diabetes: A narrative review.touchREV Endocrinol2026https://conductscience.org/library/papers/42979537PubMed
42977939Impact of co-administration of proton pump inhibitors on efficacy and safety of oral semaglutide in patients with type 2 diabetes: a single-center retrospective study.J Pharm Health Care Sci2026https://conductscience.org/library/papers/42977939PubMed
42943269Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease: A Narrative Review.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42943269PubMed
42942356Associations of TNF-α, Uric Acid, and the Leptin/Adiponectin Ratio with HOMA-IR in Hospitalized Adults: A Cross-Sectional Secondary Analysis of 147 Patients.Medicina (Kaunas)2026https://conductscience.org/library/papers/42942356PubMed
42941244ARF6: Biomarker, Therapeutic Target, and AI-Driven Precision Management for Type 2 Diabetes with Obesity.Metabolites2026https://conductscience.org/library/papers/42941244PubMed
42898214Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity.Obes Pillars2026https://conductscience.org/library/papers/42898214PubMed
42891248Social Determinants of Health and Behavioral Risk Factors in the Tuberculosis-Type 2 Diabetes Syndemic: A Narrative Review.Cureus2026https://conductscience.org/library/papers/42891248PubMed
42890326
Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy and Lifestyle Modifications for Morbid Obesity in a Patient With Paroxysmal Atrial Fibrillation, Severe Osteoarthritis, and Obstructive Sleep Apnea: A Case Report.
Cureus2026https://conductscience.org/library/papers/42890326PubMed
42889937Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity.Diabetes Obes Cardiometab CARE2026https://conductscience.org/library/papers/42889937PubMed
42851902Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42851902PubMed
42851870Patient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.Obes Sci Pract2026https://conductscience.org/library/papers/42851870PubMed
42827785Clinical and metabolic links between hypothyroidism and metabolic syndrome: a review.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42827785PubMed
42824721Association between diet quality and overweight or obesity among adults with type 2 diabetes at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia.Obes Pillars2026https://conductscience.org/library/papers/42824721PubMed
42802782Associations Between Body Mass Index Trajectories and Healthcare Utilization and Costs Among Patients with Type 2 Diabetes in Finland.Clin Epidemiol2026https://conductscience.org/library/papers/42802782PubMed
42741141Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42741141PubMed
42736522Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.Diabetes Obes Metab2026https://conductscience.org/library/papers/42736522PubMed
42707139
Prevalence, associated clinical factors, and genetic characteristics of endocrinopathies in common variable immunodeficiency: a retrospective study of 95 adult patients from a single tertiary care center.
Front Immunol2026https://conductscience.org/library/papers/42707139PubMed
42694689Exercise and physical activity interventions in type 2 diabetes mellitus.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42694689PubMed
42681751Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.Diabetes Obes Metab2026https://conductscience.org/library/papers/42681751PubMed

See all 50 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41358882

GET https://conductscience.org/api/papers/v1/41358882/references?page=2